KPV Peptide Research: Anti-Inflammatory Tripeptide and IBD Studies

# KPV Peptide Research: Anti-Inflammatory Tripeptide and IBD Studies

For research purposes only. Not for human use. All findings described below are from cell culture and animal studies; KPV has no published human clinical trials.

Introduction

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), corresponding to residues 11–13 of the parent hormone. Alpha-MSH itself is a potent endogenous anti-inflammatory signal, but its melanocortin-receptor activity brings unwanted baggage — pigmentation, appetite, and steroidogenesis effects. The research interest in KPV rests on a specific claim: that this minimal fragment retains α-MSH's anti-inflammatory activity while shedding its receptor-driven side effects.

Uniquely among peptides in this space, the KPV literature centers on inflammatory bowel disease (IBD), with a mechanistically elegant story involving the intestinal peptide transporter PepT1. This review works through that evidence, study by study, with verified citations. Supplier pricing is tracked on the KPV comparison page.

The Alpha-MSH Parent Molecule

Context on the parent hormone explains why anyone thought a three-amino-acid fragment was worth testing. Alpha-MSH is a 13-residue melanocortin peptide cleaved from pro-opiomelanocortin (POMC), best known for stimulating melanocyte pigmentation through the MC1 receptor. But decades of immunology research established it as one of the body's endogenous inflammation brakes: it suppresses NF-κB activation, downregulates pro-inflammatory cytokines, and induces the regulatory cytokine IL-10 across immune cell types. The problem as a therapeutic template is receptor promiscuity — full-length α-MSH engages MC1 through MC5 receptors, producing pigmentary, appetite, sexual-function, and steroidogenic effects that are unacceptable off-target baggage for an anti-inflammatory.

Structure-activity work localized much of the anti-inflammatory signal to the C-terminal end of the molecule. KPV — lysine-proline-valine, residues 11 through 13 — emerged as the minimal fragment retaining anti-inflammatory activity, while showing little or no melanotropic (pigmentation) activity because it lacks the His-Phe-Arg-Trp core pharmacophore that melanocortin receptors require. That dissociation is the entire premise of KPV research: inflammation control without melanocortin side effects.

The Foundational Study: PepT1-Mediated Uptake

Dalmasso et al., 2008 — Gastroenterology (PMID: 18061177). This Emory University study remains the cornerstone of KPV research and established three things:

1. Potency: nanomolar concentrations of KPV inhibited activation of NF-κB and MAP kinase inflammatory signaling in human intestinal epithelial cells (Caco2-BBE, HT29-Cl.19A) and human Jurkat T cells, reducing pro-inflammatory cytokine secretion

2. Mechanism of entry: KPV is transported into cells by PepT1, the di/tripeptide transporter — competition and radiolabeled-uptake experiments characterized the kinetics directly. This matters because PepT1 is normally expressed in the small intestine and is induced in the colon during IBD, meaning inflamed colonic tissue preferentially imports the peptide

3. In vivo efficacy: oral KPV in drinking water reduced the severity of both DSS-induced colitis (a ulcerative-colitis-like model) and TNBS-induced colitis (a Crohn's-like model) in mice, at the histological and cytokine-expression level

The PepT1 route is a genuinely distinctive mechanism: it implies KPV can act intracellularly in epithelial and immune cells without requiring classical melanocortin receptor engagement at the cell surface.

Independent confirmation the same year: Kannengiesser et al., Inflammatory Bowel Diseases, 2008 (PMID: 18092346) — a German group independently reported that melanocortin-derived tripeptide KPV had anti-inflammatory effects in murine IBD models, reducing disease activity in both dextran-sulfate and transfer-colitis settings.

Colitis-Associated Cancer

Viennois et al., 2016 — Cellular and Molecular Gastroenterology and Hepatology (PMID: 27458604). Follow-up work from the same research ecosystem examined chronic inflammation's endpoint: colitis-associated colorectal cancer. The study found PepT1 plays a critical role in promoting colitis-associated tumorigenesis, and that the anti-inflammatory tripeptide KPV provided therapeutic benefit in that model — extending the KPV story from acute inflammation to inflammation-driven cancer risk in mice.

Delivery Engineering: The Nanoparticle and Hydrogel Studies

Oral peptides face degradation before reaching the colon. Two bioengineering programs have used KPV as their payload:

Xiao et al., 2017 — Molecular Therapy (PMID: 28143741). Hyaluronic-acid-functionalized polymeric nanoparticles loaded with KPV, embedded in a chitosan/alginate hydrogel for oral delivery, targeted inflamed colonic tissue in mice. Orally delivered HA-KPV nanoparticles alleviated ulcerative-colitis-model inflammation and accelerated mucosal healing — with the striking efficiency finding that the nanoparticle formulation achieved efficacy at a KPV dose orders of magnitude below free-peptide dosing.

Self-cross-linked hydrogel work, 2021 — ACS Biomaterials Science & Engineering (PMID: 34547895). A cysteamine-grafted γ-polyglutamic-acid hydrogel stabilized KPV for colitis treatment, again showing reduced inflammation in murine colitis — evidence that the delivery-engineering interest in KPV as an IBD payload continues.

For researchers, these studies double as strong indirect evidence of the core pharmacology: multiple independent groups selected KPV as their anti-inflammatory payload precisely because its colitis efficacy is reproducible in mouse models.

Mechanism Summary

Across the literature, KPV's documented actions include:

• •Inhibition of NF-κB nuclear translocation and MAP-kinase signaling in epithelial and immune cells (PMID: 18061177)
• •Reduced secretion of pro-inflammatory cytokines (TNF-α, IL-6, IL-8) in stimulated cells
• •PepT1-mediated cellular uptake, concentrating activity in inflamed intestinal tissue (PMID: 18061177)
• •Improved histology, reduced weight loss, and lower cytokine expression in DSS and TNBS colitis models (PMIDs: 18061177, 18092346)
• •Reduced tumor burden in colitis-associated cancer models (PMID: 27458604)

Whether KPV requires any melanocortin-receptor interaction remains debated; the PepT1/intracellular route is the best-supported entry mechanism in the intestinal context.

How the Colitis Models Work

Because the entire KPV efficacy case rests on two mouse models, understanding them calibrates the evidence. DSS colitis is induced by adding dextran sodium sulfate to drinking water; the polymer is directly toxic to colonic epithelium, producing erosions, bloody diarrhea, and weight loss that histologically resemble ulcerative colitis. It primarily tests epithelial injury and innate-immune inflammation. TNBS colitis instead uses an intrarectal haptenizing agent that provokes a T-cell-driven, transmural inflammation closer to Crohn's disease immunology. A compound active in both models — as KPV was in the foundational Gastroenterology study (PMID: 18061177) — is affecting shared inflammatory machinery rather than a model-specific artifact, which is why the dual-model result carried weight. Typical readouts across the KPV studies include disease-activity scores (weight, stool consistency, bleeding), colon length, histological damage scores, myeloperoxidase activity as a neutrophil-infiltration proxy, and qPCR cytokine panels. Still, both are acute chemical-injury models in mice; neither replicates the chronic, relapsing, microbiome-entangled biology of human IBD, which is precisely the translation gap that only clinical trials could close.

What the Evidence Does Not Show

• •No human clinical trials of KPV exist — no IBD trial, no safety study, no pharmacokinetic data in humans
• •Gut-barrier and wound-healing claims circulating in research communities extrapolate mostly from cell culture and the mouse colitis data
• •Systemic (injectable) KPV has far less published support than the oral/intestinal route that defines the strongest studies — notable, since the PepT1 targeting story is specifically an argument for luminal delivery
• •Dosing in research protocols cannot be anchored to any human data

Evidence Quality Assessment

KPV sits in a middle tier of evidence: a coherent, independently replicated animal-and-mechanism story focused on gut inflammation, but zero human translation. Researchers comparing gut-focused peptides can see how it stacks against BPC-157 and LL-37 in our gut-healing peptide comparison.

Research Tools

Current supplier listings and pricing are on the KPV comparison page. For reconstitution and concentration math in research settings, use the peptide calculator.

FAQ

What is KPV derived from?

It is the C-terminal tripeptide (residues 11–13, Lys-Pro-Val) of alpha-melanocyte-stimulating hormone, retaining the fragment most associated with α-MSH's anti-inflammatory signaling.

How does KPV get into cells?

Via PepT1, the intestinal di/tripeptide transporter — characterized directly with radiolabeled uptake kinetics (PMID: 18061177). PepT1 induction in inflamed colon concentrates the effect where inflammation is active.

Has KPV been tested in humans?

No. Its evidence base is cell culture plus mouse colitis, transfer-colitis, and colitis-associated-cancer models. No human trial of KPV in any indication has been published.

Why is KPV studied for IBD specifically?

Because its uptake transporter PepT1 is upregulated in inflamed colon, and oral KPV improved both ulcerative-colitis-like (DSS) and Crohn's-like (TNBS) mouse models in the foundational studies.

References

1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID: 18061177

2. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008. PMID: 18092346

3. Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory tripeptide KPV. Cell Mol Gastroenterol Hepatol. 2016. PMID: 27458604

4. Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. PMID: 28143741

5. Self-cross-linked hydrogel of cysteamine-grafted γ-polyglutamic acid stabilized tripeptide KPV for alleviating colitis. ACS Biomater Sci Eng. 2021. PMID: 34547895

---

This article is for informational and research purposes only. KPV research materials are not for human consumption.